UNICHEM LABORATORIES LTD. - 506690 - Shareholding for the Period Ended March 31, 2021
Unichem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here16-04-2021
16-04-2021
UNICHEM LABORATORIES LTD. - 506690 - Regulation 40(9) & 40(10) Of Listing Regulations
Regulation 40(9) & 40(10) of Listing Regulations12-04-2021
UNICHEM LABORATORIES LTD. - 506690 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74[5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2021.12-04-2021
UNICHEM LABORATORIES LTD. - 506690 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Pradeep BhandariDesignation :- Company Secretary and Compliance Officer12-04-2021
UNICHEM LABORATORIES LTD. - 506690 - Compliance Certificate For The Period October 1, 2020 To March 31, 2021 (Both Days Inclusive)
Compliance Certificate for the period October 1, 2020 to March 31, 2021 (both days inclusive)10-04-2021
UNICHEM LABORATORIES LTD. - 506690 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Conduct, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 duly amended, the Trading Window for dealing in shares of the Company will be closed from April 1, 2021 for Designated Persons, Directors, Insiders and their Immediate Relatives and shall open 48 (forty eight) hours after the financial results for the quarter and year ended March 31, 2021 are made public.31-03-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Guanfacine Tablets.04-03-2021
Unichem Labs gets USFDA nod for plaque psoriasis drug
Apremilast tablets are used to treat adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy19-02-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Apremilast Tablets, 10 mg, 20 mg and 30 mg.19-02-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Financial Results for quarter and nine months ended December 31, 2020 published in newspapers on February 1, 2021.02-02-2021